Increased US prescription trends associated with the CDC Bacillus anthracis antimicrobial postexposure prophylaxis campaign

Pharmacoepidemiology and Drug Safety

Volumn 12, Issue 3, 2003, Pages 177-182

  Shaffer, Douglas ^a   Armstrong, George ^a   Higgins, Karen ^a   Honig, Peter ^a   Coyne, Philip ^a   Boxwell, Debra ^a   Beitz, Julie ^a   Leissa, Brad ^a   Murphy, Dianne ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Amoxicillin; Anthrax; Ciprofloxacin; Doxycycline; Drug utilization; Postexposure; Prophylaxis

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFUROXIME; CIPROFLOXACIN; DOXYCYCLINE;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; DATA BASE; DRUG UTILIZATION; ENVIRONMENTAL EXPOSURE; HEALTH PROMOTION; HUMAN; INFECTION CONTROL; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BIOTERRORISM; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); DRUG UTILIZATION; HUMANS; INHALATION EXPOSURE; PRESCRIPTIONS, DRUG; SPORES, BACTERIAL; UNITED STATES;

EID: 0037390866     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.828     Document Type: Article

References (20)

1. Update. investigation of anthrax associated, with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 889-893.
2. Bush LM, Abrams BH, Beall A, Johnson CC. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 2001; 345: 1607-1610.
3. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 909-919.
4. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep 2001; 50: 941-948.
5. Update: investigation of bioterrorism-related anthrax, 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 1008-1010.
6. Update: investigation of bioterrorism-related inhalational anthrax, Connecticut, 2001. MMWR Morb Mortal Wkly Rep 2001; 50: 1029-1031.
7. Shepard C, Montse Soriano-Gabarro, Zell E, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002; 10(8): 1124-1132.
8. Interim guidelines for investigation of and response to Bacillus anthracis exposures. MMWR Morb Mortal Wkly Rep 2001; 50: 987-990.
9. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001; 50: 960.
10. Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR Morb Mortal Wkly Rep 2001; 50: 1014-1016.
11. Young D. National pharmaceutical stockpile aids homeland health security. Am J Health Syst Pharm 2001; 58: 2115-2116.
12. National Center for Environmental Health. National Pharmaceutical Stockpile Program. Available from: URL: http://www.cdc.gov/nceh/nps/default.htm [1 November 2002].
13. Lewin T. A nation challenged: medications - bioterrorism and anxiety are swelling prescriptions. The New York Times 2001; 1 November: 10.
14. Smith S, Farber M. Ciprofloxacin frenzy. Am J Health Syst Pharm 2001; 58: 2250.
15. IMS HEALTH. Available from: URL: http://www.imshealth.com/ [1 November 2002].
16. Personal communication/verification. IMS HEALTH. IMS HEALTH, Public Relations. (800)-523-5333. 19 November 2002.
17. Cohen L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 1992; 257: 1050-1055.
18. Hooton T, Levy S. Antimicrobial resistance: a plan of action for community practice. Am Fam Physician 2001; 63: 1087-1098.
19. Notice to readers: evaluation of postexposure antibiotic prophylaxis to prevent anthrax. MMWR Morb Mortal Wkly Rep 2002; 51: 59.
20. Gerberding L, Hughes J, Koplan J. Bioterrorism preparedness and response. Clinicians and public health agencies as essential partners. JAMA 2002; 287: 898-900.